NanoLogix, Inc. (NNLX) Announces European Clinical Trial of Its Rapid Detection Kits  
6/7/2011 8:54:58 AM

HUBBARD, Ohio--(BUSINESS WIRE)--NanoLogix (PINK SHEETS: NNLX), a biotechnology innovator in the rapid detection and identification of live-cell bacteria and microorganisms, announced today its BioNanoFilter (BNF) technology will undergo a clinical trial, led by Dr. Gian Carlo Di Renzo of the University of Perugia in Italy. The 300 patient trial will study the speed and accuracy of NanoLogix technology compared to current methods in the detection and identification of Group B Streptococcus (GBS) in pregnant women. Initial BNF results on GBS from the University of Texas Health Science Center-Houston show detection and identification within two to six hours. This is eight to twenty-four times faster than conventional methods. The trial will be the second clinical trial conducted on the NanoLogix BNF technology for Group B Strep. Results from this clinical trial will accelerate the approval of the BNF kits for use in Europe, North Africa and the Middle East.